B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Clinical trials for B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 explained in plain language.
Never miss a new study
Get alerted when new B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 trials appear
Sign up with your email to follow new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo shows promise against tough leukemia
Disease control OngoingThis study tests a powerful chemotherapy regimen (Hyper-CVAD) combined with the targeted drug ponatinib in people with a specific type of acute lymphoblastic leukemia (ALL) that has a genetic change called the Philadelphia chromosome. The goal is to see if this combination can be…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:03 UTC
-
Promising new combo therapy for leukemia patients shows potential in major trial
Disease control OngoingThis study is for adults with a specific type of leukemia (BCR-ABL-positive ALL). It compares the usual treatment (steroids, a targeted drug, and chemo) to the same treatment plus an extra drug called blinatumomab. The goal is to see if adding blinatumomab helps people live longe…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:25 UTC
-
New drug cocktail shows promise against rare leukemia
Disease control OngoingThis early-stage trial tests a combination of the oral drug venetoclax with standard chemotherapy and targeted therapies in adults with a specific, hard-to-treat leukemia (Ph+ ALL) that is either newly diagnosed or has returned. The main goal is to find the safest dose and see ho…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 26, 2026 07:25 UTC
-
New combo therapy shows promise for older leukemia patients
Disease control OngoingThis study tested a treatment plan for adults aged 65 and older with a type of blood cancer called acute lymphoblastic leukemia (ALL). The approach combined an immunotherapy drug (blinatumomab) with standard chemotherapy or another targeted drug (dasatinib). The goal was to see i…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Liver shield: nutrient may prevent chemo side effects in young leukemia patients
Disease control OngoingThis study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. Liver toxicity from the chemo drug asparaginase often delays treatment, especially in cert…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 22, 2026 13:52 UTC